Leucine Supplementation Strategies to Enhance Muscle Anabolic Responses in Older Age

Status: Recruiting
Location: See location...
Intervention Type: Dietary supplement
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Sarcopenia describes the progressive decline of muscle mass and strength with advancing age and is associated with increased frailty and morbidity, however we do not currently have an effective treatment. Protein feeding and exercise is known to increase muscle mass, but aged muscle shows a lower response to these stimuli leading to muscle loss over time. We do know that ingesting leucine, a building block of protein, can overcome this reduced response to protein feeding and exercise leading to increased muscle mass in older people. However, we do not understand when the optimum time to ingest leucine is to maximise muscle mass after exercise in older people. In this study we will examine the effect of feeding leucine after exercise either with a meal or between meals.

Eligibility
Participation Requirements
Sex: Male
Minimum Age: 65
Maximum Age: 75
Healthy Volunteers: t
View:

• Male, 65-75 years of age

• BMI 18-28 kg/m2

• Non smoker

• Not performing regular resistance type exercise

• Participant is willing and able to give informed consent for participation in the study

Locations
Other Locations
United Kingdom
University of Nottingham
RECRUITING
Nottingham
Contact Information
Primary
Joanne Mallinson, PhD
joanne.mallinson@nottingham.ac.uk
01158230127
Backup
Matthew Brook, PhD
matthew.brook@nottingham.ac.uk
Time Frame
Start Date: 2024-08-05
Estimated Completion Date: 2026-08-05
Participants
Target number of participants: 10
Treatments
Experimental: Leucine supplementation between meals
Volunteers will take leucine supplements between breakfast and lunch, between lunch and dinner, and between dinner and supper.
Experimental: Leucine supplementation with meals
Volunteers will take leucine supplements with breakfast, with lunch and with dinner.
Related Therapeutic Areas
Sponsors
Leads: University of Nottingham

This content was sourced from clinicaltrials.gov